EP3011972A4 - Medicinal composition for promoting synthesis of protoporphyrin ix - Google Patents

Medicinal composition for promoting synthesis of protoporphyrin ix Download PDF

Info

Publication number
EP3011972A4
EP3011972A4 EP14814295.3A EP14814295A EP3011972A4 EP 3011972 A4 EP3011972 A4 EP 3011972A4 EP 14814295 A EP14814295 A EP 14814295A EP 3011972 A4 EP3011972 A4 EP 3011972A4
Authority
EP
European Patent Office
Prior art keywords
protoporphyrin
medicinal composition
promoting synthesis
promoting
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP14814295.3A
Other languages
German (de)
French (fr)
Other versions
EP3011972B1 (en
EP3011972A1 (en
Inventor
Masahiro Ishizuka
Urara OTA
Atsuko KAMIYA
Kiwamu Takahashi
Tohru Tanaka
Toshiyuki Ozawa
Kuniyuki MORIMOTO
Keitaro Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka University NUC
Osaka City University PUC
SBI Pharmaceuticals Co Ltd
Original Assignee
Osaka University NUC
Osaka City University PUC
SBI Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, Osaka City University PUC, SBI Pharmaceuticals Co Ltd filed Critical Osaka University NUC
Priority to PL14814295T priority Critical patent/PL3011972T3/en
Publication of EP3011972A1 publication Critical patent/EP3011972A1/en
Publication of EP3011972A4 publication Critical patent/EP3011972A4/en
Application granted granted Critical
Publication of EP3011972B1 publication Critical patent/EP3011972B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP14814295.3A 2013-06-19 2014-06-13 Medicinal composition for promoting synthesis of protoporphyrin ix Active EP3011972B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL14814295T PL3011972T3 (en) 2013-06-19 2014-06-13 Medicinal composition for promoting synthesis of protoporphyrin ix

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013129057 2013-06-19
PCT/JP2014/065813 WO2014203833A1 (en) 2013-06-19 2014-06-13 Medicinal composition for promoting synthesis of protoporphyrin ix

Publications (3)

Publication Number Publication Date
EP3011972A1 EP3011972A1 (en) 2016-04-27
EP3011972A4 true EP3011972A4 (en) 2017-03-01
EP3011972B1 EP3011972B1 (en) 2019-10-23

Family

ID=52104568

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14814295.3A Active EP3011972B1 (en) 2013-06-19 2014-06-13 Medicinal composition for promoting synthesis of protoporphyrin ix

Country Status (11)

Country Link
US (1) US9603928B2 (en)
EP (1) EP3011972B1 (en)
JP (1) JP6051305B2 (en)
CN (2) CN112057627A (en)
DK (1) DK3011972T3 (en)
ES (1) ES2755303T3 (en)
HK (2) HK1218628A1 (en)
HU (1) HUE046458T2 (en)
PL (1) PL3011972T3 (en)
PT (1) PT3011972T (en)
WO (1) WO2014203833A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3011972T3 (en) 2013-06-19 2019-11-04 Sbi Pharmaceuticals Co Ltd Medical composition for promoting synthesis of protoporphyrin IX
WO2017035582A1 (en) * 2015-08-31 2017-03-09 The University Of Adelaide Methods and products for preventing and/or treating microorganism infections comprising iron chelators and non-iron porphyrins
CA3158038A1 (en) * 2017-08-16 2019-02-21 Suncor Energy Inc. Photodynamic inhibition of microbial pathogens in plants
CN109821017A (en) * 2019-03-20 2019-05-31 天津医科大学 5-ALA and iron chelating agent are preparing the application in antineoplastic combination drug

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041855A1 (en) * 1996-05-08 1997-11-13 New York Blood Center, Inc. Method for treating viral infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07133277A (en) 1993-11-09 1995-05-23 Yamanouchi Pharmaceut Co Ltd Carbapenem derivative
GB0118251D0 (en) * 2001-07-26 2001-09-19 Photocure Asa Method
CN100496246C (en) 2004-06-07 2009-06-10 辛根塔参与股份公司 Methods of reducing nematode damage
JP5535808B2 (en) 2010-07-28 2014-07-02 富士フイルム株式会社 Astaxanthin-containing aqueous composition, cosmetic, and method for inhibiting astaxanthin degradation
DK3011972T3 (en) 2013-06-19 2019-11-04 Sbi Pharmaceuticals Co Ltd Medical composition for promoting synthesis of protoporphyrin IX

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041855A1 (en) * 1996-05-08 1997-11-13 New York Blood Center, Inc. Method for treating viral infections

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHIA-FEN LEE ET AL: "[delta]-Aminolaevulinic acid mediated photodynamic antimicrobial chemotherapy on Pseudomonas aeruginosa planktonic and biofilm cultures", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY, vol. 75, no. 1-2, 1 July 2004 (2004-07-01), pages 21 - 25, XP055301194, DOI: 10.1016/j.jphotobiol.2004.04.003 *
See also references of WO2014203833A1 *
SMETANA Z ET AL: "TREATMENT OF VIRAL INFECTIONS WITH 5-AMINOLEVULINIC ACID AND LIGHT", LASERS IN SURGERY AND MEDICINE, WILEY- LISS, NEW YORK, US, vol. 21, 1 January 1997 (1997-01-01), pages 351 - 358, XP000826798, ISSN: 0196-8092, DOI: 10.1002/(SICI)1096-9101(1997)21:4<351::AID-LSM6>3.0.CO;2-P *

Also Published As

Publication number Publication date
JPWO2014203833A1 (en) 2017-02-23
PL3011972T3 (en) 2020-02-28
JP6051305B2 (en) 2016-12-27
EP3011972B1 (en) 2019-10-23
HK1221904A1 (en) 2017-06-16
ES2755303T3 (en) 2020-04-22
WO2014203833A1 (en) 2014-12-24
CN112057627A (en) 2020-12-11
US9603928B2 (en) 2017-03-28
CN105555312A (en) 2016-05-04
US20160136274A1 (en) 2016-05-19
DK3011972T3 (en) 2019-11-04
HK1218628A1 (en) 2017-03-03
PT3011972T (en) 2019-11-20
EP3011972A1 (en) 2016-04-27
HUE046458T2 (en) 2020-03-30

Similar Documents

Publication Publication Date Title
HK1207861A1 (en) Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1
PT2818482T (en) Pharmaceutical composition for treatment of cancer
PL2824114T3 (en) Pharmaceutical composition for treatment of cancer
IL264259A (en) Oral formulations of pyrrolidine derivatives
EP2964028A4 (en) Compounds for treatment of cancer
EP3038465A4 (en) Oral pharmaceutical formulation of omarigliptin
HK1217443A1 (en) Pharmaceutical compositions for oral treatment of diabetes
EP2953605A4 (en) Use of cosmetic composition
EP3055281A4 (en) Preparation of hydroxy-benzylbenzene derivatives
EP3062790A4 (en) Pharmaceutical combinations for the treatment of cancer
EP2991618B8 (en) Stable high strength pharmaceutical composition of levoleucovorin
IL245771A0 (en) Synthesis and formulations of porphyrin compounds
SI2812013T1 (en) Formulation for the treatment of ibs
HK1221904A1 (en) Medicinal composition for promoting synthesis of protoporphyrin ix ix
EP3046532A4 (en) Oral care composition
EP3079721A4 (en) Pharmaceutical compositions of carotenoid
EP3046537A4 (en) Pharmaceutical preparation of carbohydrates for therapeutic use
EP2948143A4 (en) Use of phenoxypropylamine compounds to treat depression
EP3065746A4 (en) Therapeutic compositions
EP3082783A4 (en) Stable oral pharmaceutical composition
IL240119A0 (en) Pharmaceutical compositions for oral treatment of diabetes
EP3052475A4 (en) Pharmaceutical use of 3-benzylsulfonylpropionitrile
EP3049072A4 (en) Synthesis of delta 12-pgj3 and related compounds
AU2013902855A0 (en) Therapeutic composition
AU2013904308A0 (en) Therapeutic compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160105

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170130

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/19 20060101ALI20170124BHEP

Ipc: A61K 41/00 20060101AFI20170124BHEP

Ipc: A61K 33/40 20060101ALI20170124BHEP

Ipc: A61P 31/04 20060101ALI20170124BHEP

Ipc: A61K 31/198 20060101ALI20170124BHEP

Ipc: A61K 31/375 20060101ALI20170124BHEP

Ipc: A61K 45/00 20060101ALI20170124BHEP

Ipc: A61K 31/194 20060101ALI20170124BHEP

Ipc: A61P 43/00 20060101ALI20170124BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1221904

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180503

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190619

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENT- UND MARKENANWAELTE, CH

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20191101

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014055673

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1192934

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191115

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3011972

Country of ref document: PT

Date of ref document: 20191120

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20191111

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20191023

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E046458

Country of ref document: HU

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 33355

Country of ref document: SK

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2755303

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200422

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200123

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200124

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014055673

Country of ref document: DE

PG2D Information on lapse in contracting state deleted

Ref country code: IS

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200223

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

26N No opposition filed

Effective date: 20200724

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200613

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1192934

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191023

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20220610

Year of fee payment: 9

Ref country code: SE

Payment date: 20220620

Year of fee payment: 9

Ref country code: PT

Payment date: 20220602

Year of fee payment: 9

Ref country code: NO

Payment date: 20220622

Year of fee payment: 9

Ref country code: NL

Payment date: 20220620

Year of fee payment: 9

Ref country code: IT

Payment date: 20220627

Year of fee payment: 9

Ref country code: IE

Payment date: 20220621

Year of fee payment: 9

Ref country code: HU

Payment date: 20220617

Year of fee payment: 9

Ref country code: GB

Payment date: 20220627

Year of fee payment: 9

Ref country code: DK

Payment date: 20220622

Year of fee payment: 9

Ref country code: DE

Payment date: 20220531

Year of fee payment: 9

Ref country code: CZ

Payment date: 20220610

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20220610

Year of fee payment: 9

Ref country code: PL

Payment date: 20220607

Year of fee payment: 9

Ref country code: FI

Payment date: 20220621

Year of fee payment: 9

Ref country code: BE

Payment date: 20220620

Year of fee payment: 9

Ref country code: AT

Payment date: 20220621

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20220628

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20220830

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20220630

Year of fee payment: 9

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602014055673

Country of ref document: DE

REG Reference to a national code

Ref country code: NO

Ref legal event code: MMEP

Ref country code: DK

Ref legal event code: EBP

Effective date: 20230630

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 33355

Country of ref document: SK

Effective date: 20230613

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231213

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230613

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230613

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20230701

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 1192934

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230613

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20230630

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20230613

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230613

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230614

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240103

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230613

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230613

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230613

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230630

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230630

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230630

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230614

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230630

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20240730

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230613

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230630